Vericel shareholders approve amended 2022 equity plan and ESPP at April 30 meeting
At its April 30, 2025 annual meeting, Vericel shareholders approved an amended and restated 2022 Omnibus Incentive Plan and an amended and restated 2015 Employee Stock Purchase Plan. The plans reserve 5,088,095 and 2,000,000 shares of common stock for issuance, respectively. All seven director nominees were elected, and shareholders also approved the non-binding advisory vote on executive compensation.
Key points
- Equity plan reserves 5,088,095 shares of common stock for issuance; effective April 30, 2025.
- Employee Stock Purchase Plan reserves 2,000,000 shares of common stock.
- All seven director nominees elected to one-year terms expiring at the 2026 annual meeting.
- Non-binding say-on-pay vote: 40,777,685 votes for and 4,353,149 against.
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:49 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 02, 2025.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.